CA2546794C - Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients - Google Patents

Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients Download PDF

Info

Publication number
CA2546794C
CA2546794C CA2546794A CA2546794A CA2546794C CA 2546794 C CA2546794 C CA 2546794C CA 2546794 A CA2546794 A CA 2546794A CA 2546794 A CA2546794 A CA 2546794A CA 2546794 C CA2546794 C CA 2546794C
Authority
CA
Canada
Prior art keywords
peptide
hla
cancer
cells
bci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2546794A
Other languages
English (en)
French (fr)
Other versions
CA2546794A1 (en
Inventor
Eivind Per Thor Straten
Mads Hald Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Survac ApS
Original Assignee
Survac ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Survac ApS filed Critical Survac ApS
Publication of CA2546794A1 publication Critical patent/CA2546794A1/en
Application granted granted Critical
Publication of CA2546794C publication Critical patent/CA2546794C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2546794A 2003-11-19 2004-11-18 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients Expired - Lifetime CA2546794C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52311903P 2003-11-19 2003-11-19
US60/523,119 2003-11-19
DKPA200301716 2003-11-19
DKPA200301716 2003-11-19
PCT/DK2004/000799 WO2005049073A2 (en) 2003-11-19 2004-11-18 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients

Publications (2)

Publication Number Publication Date
CA2546794A1 CA2546794A1 (en) 2005-06-02
CA2546794C true CA2546794C (en) 2013-09-17

Family

ID=39149116

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2546794A Expired - Lifetime CA2546794C (en) 2003-11-19 2004-11-18 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients

Country Status (17)

Country Link
US (1) US7842294B2 (enExample)
EP (2) EP1691824B1 (enExample)
JP (2) JP4926714B2 (enExample)
KR (2) KR101284237B1 (enExample)
CN (1) CN1921878B (enExample)
AT (1) ATE424842T1 (enExample)
AU (1) AU2004290866B2 (enExample)
CA (1) CA2546794C (enExample)
DE (1) DE602004019965D1 (enExample)
DK (2) DK2087904T3 (enExample)
ES (2) ES2436429T3 (enExample)
MX (1) MXPA06005738A (enExample)
PL (2) PL2087904T3 (enExample)
PT (1) PT1691824E (enExample)
RU (1) RU2367468C2 (enExample)
WO (1) WO2005049073A2 (enExample)
ZA (1) ZA200604866B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
ES2661082T3 (es) * 2003-01-30 2018-03-27 Survac Aps Péptidos derivados de survivina y uso de los mismos
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
CN101438437A (zh) * 2004-10-19 2009-05-20 麻省理工学院 用于自组装、柔软和轻的锂电池组的病毒支架
AU2011203535B2 (en) * 2005-02-04 2012-10-11 Survac Aps Survivin peptide vaccine
EP1853305B1 (en) * 2005-02-04 2014-08-20 Survac ApS Survivin peptide vaccine
AU2006347606B2 (en) * 2005-09-09 2012-10-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cell proliferation
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3620465B1 (en) * 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
EP2254592B1 (en) * 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
AU2009246876B2 (en) 2008-05-16 2015-04-02 Htyr Acquisition Llc Antibodies and processes for preparing the same
CA2730369A1 (en) * 2008-07-16 2010-01-21 Burnham Institute For Medical Research Compositions and methods for modulating nod-like receptor activity and uses thereof
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
CA2735522C (en) 2008-08-28 2017-04-18 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
AU2009305617B2 (en) 2008-10-17 2014-01-23 University Of Miami Tumor vaccine
EP3444333A1 (en) * 2009-10-22 2019-02-20 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
CN102884190B (zh) 2010-03-11 2016-03-23 肿瘤疗法科学股份有限公司 Hjurp肽及包含它们的疫苗
EP2608799B1 (en) * 2010-08-24 2018-12-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
SI3536334T1 (sl) 2012-05-16 2021-11-30 Stemline Therapeutics Inc. Cepiva proti raku, ki ciljajo na rakave matične celice
SG10201700459XA (en) * 2012-07-20 2017-02-27 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US20160017011A1 (en) * 2013-02-26 2016-01-21 Rongfu Wang Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
CA2902423C (en) * 2013-03-01 2021-06-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
US9704181B2 (en) * 2014-05-06 2017-07-11 International Business Machines Corporation Real-time social group based bidding system
CN113786476A (zh) 2016-12-02 2021-12-14 泰加生物工艺学公司 纳米颗粒调配物
TWI796314B (zh) * 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
CR20210128A (es) 2017-01-27 2021-04-26 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cancer (divisional exp. 2019-388)
US11666644B2 (en) 2018-09-04 2023-06-06 Treos Bio Limited Peptide vaccines
EP3898666A2 (en) 2018-12-17 2021-10-27 Immudex ApS Panel comprising borrelia mhc multimers
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
EP3969041A4 (en) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
CN113355432A (zh) * 2021-05-12 2021-09-07 甘肃农业大学 Bmf作为细胞凋亡标志物的应用
WO2022245249A1 (ru) * 2021-05-17 2022-11-24 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Пептидные соединения для индукции апоптоза в опухолевой клетке

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
ATE280180T1 (de) 1992-08-31 2004-11-15 Ludwig Inst Cancer Res Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US5470955A (en) 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5789201A (en) * 1996-02-23 1998-08-04 Cocensys, Inc. Genes coding for bcl-y a bcl-2 homologue
US6245523B1 (en) 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
WO1998058541A1 (en) * 1997-06-24 1998-12-30 Dana-Farber Cancer Institute, Inc. Modulation of apoptosis
WO2001036594A1 (en) * 1999-11-16 2001-05-25 Dartmouth College Mcl-1 GENE REGULATORY ELEMENTS AND A PRO-APOPTOTIC Mcl-1 VARIANT
AU2578401A (en) * 1999-12-14 2001-06-25 Burnham Institute, The Bcl-g polypeptides, encoding nucleic acids and methods of use
WO2002005835A2 (en) * 2000-07-17 2002-01-24 Washington University Modulation of apoptosis
AU2002257647A1 (en) 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
AU2004228106B2 (en) 2003-04-11 2010-05-13 Survac Aps Therapeutic cancer vaccine

Also Published As

Publication number Publication date
KR101216655B1 (ko) 2013-01-02
US20080050396A1 (en) 2008-02-28
CN1921878A (zh) 2007-02-28
ES2323588T3 (es) 2009-07-21
DE602004019965D1 (de) 2009-04-23
AU2004290866B2 (en) 2010-09-02
EP1691824B1 (en) 2009-03-11
CN1921878B (zh) 2012-04-25
EP2087904B1 (en) 2013-08-28
ZA200604866B (en) 2008-05-28
EP2087904A1 (en) 2009-08-12
JP5502823B2 (ja) 2014-05-28
WO2005049073A3 (en) 2006-01-05
DK1691824T3 (da) 2009-07-06
MXPA06005738A (es) 2006-12-14
JP4926714B2 (ja) 2012-05-09
ES2436429T3 (es) 2014-01-02
WO2005049073A2 (en) 2005-06-02
JP2007511547A (ja) 2007-05-10
CA2546794A1 (en) 2005-06-02
AU2004290866A1 (en) 2005-06-02
KR20060132622A (ko) 2006-12-21
JP2011246496A (ja) 2011-12-08
US7842294B2 (en) 2010-11-30
DK2087904T3 (da) 2013-12-02
PT1691824E (pt) 2009-05-28
KR20130026527A (ko) 2013-03-13
EP1691824A2 (en) 2006-08-23
RU2006121466A (ru) 2007-12-27
PL1691824T3 (pl) 2009-08-31
KR101284237B1 (ko) 2013-07-09
ATE424842T1 (de) 2009-03-15
HK1101131A1 (en) 2007-10-12
RU2367468C2 (ru) 2009-09-20
PL2087904T3 (pl) 2014-01-31

Similar Documents

Publication Publication Date Title
CA2546794C (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
USRE48522E1 (en) Survivin-derived peptides and uses thereof
JP4365405B2 (ja) Ｍｈｃ分子と結合する腫瘍関連ペプチド
EP2857035B1 (en) Survivin-derived peptides and use thereof
HK1101131B (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
HK1209050B (en) Survivin-derived peptides and use thereof
HK1209049B (en) Survivin-derived peptides and use thereof
HK1134030B (en) Survivin-derived peptides and use thereof

Legal Events

Date Code Title Description
EEER Examination request